HLS Therapeutics

• NCT04562467

  Collaborator, Phase 4, Completed, 70 people, 24 Sept 2020

• NCT04412018

  Collaborator, Phase 2, Completed, 100 people, 2 Jun 2020

• Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3)

  Consulting or advice, Fees or honoraria, 6 Oct 2026

• Familial Hypercholesterolemia

  Consulting or advice, Fees or honoraria, Board or leadership role, 15 Sept 2026

• Predictors of aortic stenosis in homozygous familial hypercholesterolemia: A study from the Canadian HoFH registry

  Consulting or advice, Fees or honoraria, Board or leadership role, 2 Sept 2026

• Cumulative Benefit With Evolocumab in Patients With No Prior Myocardial Infarction or Stroke in the VESALIUS-CV Study

  Fees or honoraria, 28 Aug 2026

• Opportunistic Genetic Testing for Familial Hypercholesterolemia in Premature Acute Coronary Syndrome: Results of the ACCURATE Study

  Consulting or advice, Board or leadership role, 7 Aug 2026

• Rationale and Design of the Canadian Lipoprotein(a) Registry

  Consulting or advice, Fees or honoraria, 17 Jun 2026

• Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis

  Fees or honoraria, 1 Feb 2021

Sources: pubmed.ncbi.nlm.nih.gov, europepmc.org